Table 1.
Clinical Information for the Entire Cohort and by Low or High LAV/BSA
| Variable | Total (N = 201) | Low LAV/BSA (n = 101) | High LAV/BSA (n = 100) | P |
|---|---|---|---|---|
| Kidney transplants | 71 (35.3) | 40 (39.6) | 31 (31) | 0.2 |
| Age (y) | 51.6 ± 11.8 | 50.4 ± 12.6 | 52.8 ± 10.9 | 0.1 |
| Men | 145 (72.1) | 82 (81.2) | 63 (63) | 0.004 |
| BSA (m2) | 1.76 ± 0.2 | 1.77 ± 0.2 | 1.75 ± 0.2 | 0.8 |
| LAV (mL) | 56.3 ± 9.7 | 50.4 ± 6.8 | 62.3 ± 8.4 | 0.001 |
| SBP (mm Hg) | 136.9 ± 24.6 | 135.6 ± 26.2 | 138.4 ± 22.8 | 0.5 |
| DBP (mm Hg) | 80.9 ± 12.9 | 82.2 ± 13.5 | 79.3 ± 12.1 | 0.2 |
| RRT time (HD and PD only) (y) | 1.7 ± 4.3 | 1.5 ± 4.3 | 1.9 ± 4.4 | 0.5 |
| RRT type | ||||
| HD | 108 (53.7) | 56 (55.4) | 52 (52) | |
| PD | 52 (25.9) | 23 (22.8) | 29 (29) | 0.6 |
| Predialysis | 41 (20.4) | 22 (21.8) | 19 (19) | |
| Diabetes mellitus | 121 (60.2) | 61 (60.4) | 60 (60) | 0.9 |
| Ischemic heart disease | 54 (26.9) | 24 (23.8) | 30 (30) | 0.4 |
| Heart failure | 12 (6.0) | 6 (5.9) | 6 (6) | 0.9 |
| Cerebrovascular disease | 12 (6.0) | 6 (5.9) | 6 (6) | 0.9 |
| Peripheral vascular disease | 16 (8.0) | 6 (5.9) | 10 (10) | 0.3 |
| Smoking | ||||
| Never | 107 (53.2) | 56 (55.4) | 51 (51) | 0.5 |
| Current/ex | 94 (26.9) | 45 (22.8) | 49 (31) | |
| EPO receptor agonist | 151 (75.1) | 72 (71.2) | 79 (79) | 0.1 |
| Hemoglobin (g/dL) | 11.5 ± 1.7 | 11.5 ± 1.7 | 11.3 ± 1.5 | 0.2 |
| β-Adrenoceptor blocker | 87 (43.3) | 45 (44.6) | 42 (42) | 0.8 |
| Aspirin | 83 (41.3) | 38 (37.6) | 45 (45) | 0.2 |
| Warfarin | 7 (3.5) | 4 (4.0) | 3 (3) | 0.7 |
| ACEi/ARB | 54 (26.9) | 28 (27.7) | 26 (26) | 0.9 |
| Diuretic | 60 (29.6) | 31 (30.7) | 29 (29) | 0.9 |
| Calcium channel blocker | 58 (28.9) | 33 (32.7) | 25 (25) | 0.3 |
| α-Adrenoceptor blocker | 21 (10.4) | 13 (12.9) | 8 (8) | 0.3 |
| Statin | 83 (41.3) | 35 (34.7) | 48 (48) | 0.05 |
Note: Values expressed as mean ± standard deviation and number (percentage). The low-LAV/BSA group includes individuals with LAV/BSA less than the median value; the high-LAV/BSA group includes individuals with LAV/BSA equal to the median value or greater. Tests of significance are t test and χ2.
Abbreviations and definitions: ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BSA, body surface area; DBP, diastolic blood pressure; EPO, erythropoietin; HD, hemodialysis; LAV, left atrial volume; LAV/BSA, left atrial volume corrected for body surface area; PD, peritoneal dialysis; RRT, renal replacement therapy; SBP, systolic blood pressure.